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license (http://creativeetary supplements, are linked to metabolic risk factors for Alzheimer’s disease (AD). BCAA directly
influence amino acid transport to the brain and, therefore, neurotransmitter levels. We thus investi-
gated the impact of BCAA on AD neuropathology in a mouse model.
Methods: 3xTg-AD mice were fed either a control diet or a high-fat diet from 6 to 18 months of
age. For the last 2 months, dietary BCAA content was adjusted to high (150%), normal (10%),
or low (250%).
Results: Mice fed a BCAA-supplemented high-fat diet displayed higher tau neuropathology and
only four out of 13 survived. Mice on the low-BCAA diet showed higher threonine and tryptophan
cortical levels while performing better on the novel object recognition task.
Discussion: These preclinical data underscore a potential risk of combining high-fat and high BCAA
consumption, and possible benefits from BCAA restriction in AD.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Branched-chain amino acids; 3xTg-AD mice; Dietary protein; Tau pathology1. Introduction
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disease, and the number of demented patients in
the world is predicted to double within the next 15 years
because of the aging population [1]. Given the lack of
disease-modifying treatments, controlling environmental
risk factors remains an attractive opportunity to reduce the
incidence of AD [2]. Changing dietary habits has been pro-
posed as a means of delaying the onset of the disease eitheruthor. Tel.: 1(418) 525-4444x48697; Fax: 1(418)
ederic.calon@pha.ulaval.ca
/j.trci.2018.10.005
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).through direct effects on brain function or indirectly by
improving peripheral metabolic determinants [3]. Indeed,
common nutrients such as lipids, amino acids, and polyphe-
nols may have significant impact on cognitive performance
[4–6]. However, the optimal diet to be used in prevention
trials remains to be determined.
Branched-chain amino acids (BCAA; leucine, isoleucine,
and valine) are essential amino acids, comprising approxi-
mately 20% of protein intake. BCAA are commonly used
as dietary supplements, by doubling the daily intake of those
amino acids, to increase muscular mass and recovery after
exercise [7,8]. However, a BCAA-related signature is iden-
tifiable in a context of metabolic disorders: circulating
BCAA are increased in people suffering from obesity and
have been shown to predict insulin resistance and otherimer’s Association. This is an open access article under the CC BY-NC-ND
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from metabolomics studies indicate that high-fat diet (HFD)
acts in synergy with BCAA to induce metabolic disorders, at
least in animal models [11].
BCAA enter the central nervous system via the large
neutral amino acids transporter (LAT1) at the blood-brain
barrier, where they compete with tryptophan and tyrosine,
which are direct precursors to serotonin and dopamine,
respectively [12]. Thus, circulating BCAA can modulate
levels of these key neurotransmitters in the brain, thereby
altering brain function and behavior [13–16]. Because
cognitive impairments observed in AD have been
associated with a neurotransmitter imbalance [17], we hy-
pothesize that BCAA intake can modulate AD-like behavior.
Indeed, the maple syrup urine disease is a neurometabolic
disorder characterized by a toxic accumulation of BCAA
and their metabolites, which leads to severe mental retarda-
tion and encephalopathy [18,19].
It is only recently that studies have provided clues to a po-
tential link between BCAA and AD pathogenesis. A metab-
olomic analysis from the ADNI cohort recently reported
inverse correlations between plasmatic valine concentra-
tions and cognitive deficits, as well as ventricle volume in
symptomatic stages [20]. Another metabolomic study in
large prospective cohorts relates higher levels of plasma
BCAA with a lower risk of dementia [21]. Conversely, a
genome-wide association study suggests that single-
nucleotide polymorphisms (SNPs) associated with higher
plasma isoleucine levels are positively associated with the
risk for developing AD [22]. However, no studies have
focused yet on the effect of BCAA consumption on AD pa-
thology. Thus, we investigated the impact of both BCAA
supplementation and restriction in old 3xTg-AD mice, an
animal model of age-related behavioral impairments and
Ab/tau neuropathologies.2. Methods
2.1. Animals and diets
The 3xTg-AD (APPswe, PS1M146V, tauP301L) mouse
model of genetically induced AD-like neuropathology
was used with an equal number of males and females in
each group. Mice produced at our animal facility received
either a control diet (CD; 12% kcal fat) or a high-fat diet
(HFD; 60% kcal fat) for a 10-month period starting at
the age of 6 months. At 16 months of age, groups of
mice were exposed until 18 months to the same diets modi-
fied to include high (150%), normal (10%), or low
(250%) BCAA content (Fig. 1A). Table 1 provides a
detailed description of the amino acids measured in the di-
ets using gas chromatography with flame ionization detec-
tor (see methods below), whereas Supplementary Table 1
contains the list of amino acids added to the formulations.
Supplementary Table 2 shows the description of fatty acids
measured in the diets using gas chromatography. Dietswere formulated and custom-made by Research Diets,
Inc. (New Brunswick, NJ) to ensure uniformity between
groups and consistency with our previous studies with
the 3xTg-AD mouse [23,24].
All mice were put under deep anesthesia with a keta-
mine/xylazine i.p. injection (100 mg/kg ketamine, 10 mg/
kg xylazine) and sacrificed by intracardiac perfusion with
50 mL of ice-cold 0.1 M phosphate buffer saline (PBS)
with a cocktail of inhibitors of phosphatases (sodium
pyrophosphate 1 mM and sodium fluoride 50 mM) and pro-
teases (SigmaFAST protease inhibitor tablets; Sigma-
Aldrich, St. Louis, USA) as described elsewhere [23].
Rapidly, one hemisphere of the brain was dissected and
frozen at 280C until processing for Western blot, ELISA,
or measurements of amino acids and neurotransmitters. All
experiments were performed in accordance with the Cana-
dian Council on Animal Care and were approved by the
Institutional Committee of the Centre Hospitalier de l’Uni-
versite Laval (CHUL).
2.2. Biochemical analyses
Aspartate aminotransferase, alanine aminotransferase,
creatine kinase, triglycerides, and cholesterol were analyzed
in plasma from intracardiac blood (centrifuged 5 min,
3000 rpm) sampled just before intracardiac perfusion at sac-
rifice with a modular analyzer (Roche). Only samples with
more than 100 mL of plasma could be analyzed with that
method. When the hemolysis level reached more than
50 g/dL, samples were eliminated from the analysis. Creat-
inine was determined with an ELISA kit (B-Bridge Interna-
tional Inc, Santa Clara, CA, USA) according to the
manufacturer’s instructions.
2.3. Behavioral assessment
Recognition memory and locomotor activity were evalu-
ated with the novel object recognition test and the open field
test, respectively, as previously described (see the
Supplementary Material) [25].
2.4. Amino acid quantification in diet, plasma, and brain
Amino acids in the diets, plasma, and cortex homoge-
nates were analyzed by gas chromatography with flame ioni-
zation detector as described in Supplementary Material [26].
2.5. Quantification of monoamines in the prefrontal cortex
and hippocampus
Dopamine (DA), serotonin (5-HT), 5-hydroxyindolacetic
acid (5-HIAA), homovanillic acid (HVA), and 3,4-
dihydroxyphenylacetic acid (DOPAC) were quantified in
the prefrontal cortex and hippocampus of mice by electro-
chemical high-performance liquid chromatography
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Fig. 1. BCAA-supplemented HFD affects the survival of 3xTg-AD mice, increasing hepatic and muscular toxicity. Timeline of experimentation (A). Survival
rate of mice fed the six different diets during a 2-month period (final vertical line indicates sacrifice) (B). Plasmatic concentrations of AST (C), ALT (D), CK (E),
and creatinine (F) from intracardiac blood of 18-month-old 3xTg-ADmice sampled just before perfusion. Samples available and analyzed frommoribund mice
are identified with a red circle. Data are presented as mean6 SEM. Mantel-Cox test: yP, .05, yyyP, .001. One-way ANOVA, Dunnett’s (versus CD-ctl) post
hoc analysis: *P, .05, **P, .01. Two-wayANOVA, followed by Tukey’s HSD, effect of the diet: &&&P, .001. Abbreviations: CD, control diet; HFD, high-fat
diet; ctl, normal levels of BCAA; high, BCAA-supplemented diet by 50%; low, BCAA-reduced diet by 50%; AST, aspartate aminotransferase; ALT, alanine
aminotransferase, CK, creatine kinase; BCAA, branched-chain amino acids.
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For Western immunoblotting and b-Amyloid ELISA,
proteins were extracted from the parieto-temporal cortex.
The protein extraction method results in a TBS-soluble
fraction (intracellular and extracellular fraction), a
detergent-soluble fraction (membrane fraction) and a
detergent-insoluble fraction (insoluble proteins resus-
pended in formic acid) as previously described [25]. The
detailed method for Western immunoblotting is described
elsewhere [24]. The list of primary antibodies used in our
experiments is available in Supplementary Table 5. Ho-
mogenates were all run on the same gel for each experi-
ment.2.7. Ab40 and Ab42 quantification
Ab40 and Ab42 were measured in TBS-soluble and
detergent-insoluble fractions from the parieto-temporal cor-
tex using sensitive human b-Amyloid ELISA kits (Wako,
Osaka, Japan) according to the manufacturer’s instructions,
as shown [24]. Plates were read at 450 nm using a Synergy
HT multidetection microplate reader (Biotek, Winooski,
VT, USA).2.8. Statistics
Data are presented as the mean 6 SEM. Statistical anal-
ysis used and the numbers of mice per group are specified
in each figure or legend. Briefly, one- (one independent var-
iable) or two-way (two independent variables) ANOVAs
were used when more than two groups were compared and
were followed by Tukey’s post hoc (equal variance). In
case of unequal variance, Dunnett’s post hoc was used or a
Kruskal-Wallis followed by Dunn’s. The log-rank Mantel-
Cox test was used for the analysis of the survival curves. Cor-
relations between variables were investigated using linear
regression analyses. All statistical analyses were performed
with Prism 5 (GraphPad software, San Diego, CA, USA) or
JMP (version 12.1.0; SAS Institute Inc., Cary, IL, USA) soft-
wares, and statistical significance was set at P , .05.3. Results
Experiments were performed in the 3xTg-AD mouse
model of AD, which develops behavioral impairments as
well as Ab and tau neuropathologies with age. Because
age-related factors are essential to the development of AD
[28,29], old 3xTg-AD mice were selected. To evaluate the
impact of BCAA on AD pathogenesis, 3xTg-AD mice were
Table 1
Description of dietary treatments
Content
Control 5% (w/w) fat High fat 35% (w/w) fat
Normal High-BCAA Low-BCAA Normal High-BCAA Low-BCAA
Protein (% w/w) 20.3 23.3 18.4 27.4 31 25
Carbohydrate (% w/w) 66 63.5 67.5 25.3 24.1 26.1
Fat (% w/w) 5 4.8 5.1 35.1 33.4 36.3
Calorie per diet weight (kcal/g) 3.9 3.9 3.9 5.3 5.2 5.3
Ingredient (g/kg)
Amino acids
L-cystine 0.2 1.8 2.5 0.4 3.4 5.2
Isoleucine 6.4 16.2 2.9 8.9 22.2 5.3
Leucine 16.3 38.4 7.3 23.3 49.9 14.2
Lysine 15.2 13.2 13.7 22.9 20.2 24.9
Methionine 7.0 4.1 4.5 9.9 6.6 8.4
Phenylalanine 10.3 10.2 11.2 14.8 14.1 21.1
Threonine 5.2 5.0 5.3 7.5 6.8 9.0
Tryptophan* 0 1.1 1.3 0 1.1 1.3
Valine 7.4 20.6 3.2 11.6 26.8 6.4
Histidine 4.4 3.8 4.3 7.3 5.7 7.2
Alanine 4.9 5.3 5.2 6.6 5.6 6.7
Arginine* 0 3.2 3.9 0 3.2 3.9
Aspartic acid 9.9 9.0 9.9 14.5 13.3 15.9
Glutamic acid 40.9 37.1 39.0 55.9 58.8 61.8
Glycine 2.5 3.1 3.3 3.7 4.6 4.9
Proline 16.6 17.2 18.8 23.8 23.8 30.7
Serine 7.4 7.5 7.4 10.7 15.4 12.2
Tyrosine 10.9 10.3 10.3 13.2 12.8 18.3
Total 166 207 154 235 294 257
Corn starch 150 150 150 25 25 25
Maltodextrin 10 0 0 0 100 100 100
Sucrose 500 500 500 52.5 52.5 52.5
Cellulose, BW200 50 50 50 50 50 50
Corn oil 30 30 30 0 0 0
Safflower oil 0 0 0 125 125 125
Lard 0 0 0 135 135 135
Soybean oil 10 10 10 0 0 0
Canola oil 10 10 10 0 0 0
Mineral (S19101) 35 35 35 35 35 35
Vitamins (V15908) 10 10 10 10 10 10
Choline bitartrate 2 2 2 2 2 2
Cholesterol, USP 0.6 0.6 0.6 3 3 3
Abbreviation: BCAA, branched-chain amino acid.
NOTE. Amino acid content of the diets, accounting for casein and amino acid supplementation, was determined by GC-FID.
*Arginine cannot be determined with the technique used and tryptophan degrades quickly during acid hydrolysis.
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diets were either supplemented or restricted in BCAA by
50% for 2 months (Table 1; Fig. 1A). Animals were exposed
to an HFD because it is more representative of prevalent die-
tary habits in Western societies [30], and also because HFD
has been shown to accelerate AD-like pathology
[23,24,31,32] and to synergize with BCAA to induce
metabolic disorders [11] in animal models.3.1. BCAA supplementation combined with HFD led to the
premature death of two-thirds of 3xTg-AD mice
At the end of the study, only four out of 13mice (30.8%) in
the group fed the HFD survived the 2-month supplementationwith BCAA, which is significantly less than the group fed an
HFD only, in which 10 mice out of 12 mice (83.3%) survived
(Fig. 1B). Interestingly, no mice restricted in BCAA for the 2-
month period died prematurely, regardless of the base diet.
Although a total of 15 animals from all groups died before
the end of the planned study, we were able to sacrifice a few
(n5 7) in the high-BCAAHFD group while they were in crit-
ical conditions, allowing collection of intracardiac blood and
brains as described in the Methods. These moribund mice
fed the combination of HFD and BCAA (identified with red
circles in Fig. 1) displayed higher aspartate aminotransferase,
alanine aminotransferase, and creatine kinase plasmatic con-
centrations (Fig. 1C, D and E), suggesting major liver,
muscular, or cardiac damage [33]. A two-way ANOVA
M. Tournissac et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 677-687 681revealed that mice fed the HFD, independently of BCAA
intake, had lowerplasmatic creatinine concentrations, possibly
due to reduced muscle mass (Fig. 1F) [34]. No differences
were found in plasma triglycerides and cholesterol levels be-
tween each group (Supplementary Table 4).3.2. Titrating BCAA supply modifies plasma and brain
amino acids and monoamines levels in 18-month-old 3xTg-
AD mice
HighBCAA consumptionwas reported to directlymodify
levels of plasmatic BCAA and aromatic amino acids (AAA)
in humans [14]. Because tryptophan, threonine, tyrosine,
valine, leucine, and isoleucine all compete for LAT1 for brain
entry, specific changes in circulating amino acidsmay impact
their balance in the brain, as well as downstream monoamin-
ergic neurotransmitters [13,14]. We thus measured levels of
amino acids in the plasma and parieto-temporal cortex
(Fig. 2). We first confirmed that BCAA restriction decreased
valine, leucine, and isoleucine concentrations in the plasma
in both CD and HFD groups, but not in the cerebral cortex
(Fig. 2A, D). Lower BCAA intake also increased the ratio
of circulating AAA to BCAA and levels of glycine and tyro-
sine under both types of diets (Fig. 2B, C). Although a 50%
higher consumption of BCAA was not reflected in signifi-
cantly higher plasmatic or cortical concentrations, increased
asparagine levels were noted in the plasma of mice supple-
mentedwith BCAA in either the CDorHFD (Fig. 2C).More-
over, threonine levels were markedly modulated in the brain
with higher and lower concentrations following low and high
BCAA intake, respectively, whether in CD or HFD (Fig. 2F).
Changes in cortical tyrosine levelswere not significant, prob-
ably due to interindividual variations (Fig. 2F), whereas
cortical concentrations of tryptophan, but not phenylalanine,
were inversely associated with levels of BCAA in the plasma
in both CD and HFD (Fig. 2F).
To confirm that modulations in plasmatic and brain amino
acids impact neurotransmitter synthesis, we measured cate-
cholamines (dopamine, DA) and indolamines (serotonin, 5-
HT) and their metabolites in the prefrontal cortex and hippo-
campus of the 3xTg-AD mice (Fig. 3). Whereas BCAA
intake did not affect DA concentrations in 3xTg-AD mice,
a trend toward higher 5-HT content was observed in both
the prefrontal cortex and hippocampus of mice fed an
HFD reduced in BCAA compared with mice fed an HFD
only (Fig. 3A, F). In addition, a low BCAA intake led to
higher levels of metabolites 5-hydroxyindoleacetic acid (5-
HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in
both the prefrontal cortex and hippocampus, compared to
the HFD supplemented with BCAA (Fig. 3B, D, G).3.3. Low BCAA dietary intake improves object recognition
memory in old 3xTg-AD mice
To assess the effect of BCAA dietary intake on memory
function, all groups of mice underwent the novel objectrecognition task at 18 months (Fig. 4A). This test requires
minimal movement and induces no anxiety, which makes
it a suitable choice for old 3xTg-AD mice [24]. The test first
confirmed that 18-month-old 3xTg-AD mice, fed either a
CD or a HFD, did not discriminate the novel from the old ob-
ject (Fig. 4B, C), as previously shown [25]. Similarly, 3xTg-
AD mice fed the high BCAA diet failed to recognize the
novel object. In contrast, 3xTg-AD mice fed the low
BCAA diets, either CD-low or HFD-low, spent significantly
more time exploring the novel than the familiar object, sug-
gesting memory improvement after BCAA restriction. The
open field test confirmed that no group of mice demonstrated
impaired voluntary locomotor activity, which could have
affected exploratory behavior (Fig. 4D). The time the mice
spent on a wire confirms that muscular strength was not
affected by dietary treatments (Supplementary Fig.1). Inter-
estingly, cortical threonine levels were correlated with the
recognition index (Fig. 4E).3.4. BCAA supplementation in an HFD context worsens
tau hyperphosphorylation but not amyloid pathology in old
3xTg-AD mice
Tau hyperphosphorylation is one of the main neuropath-
ological hallmarks of AD, correlating with cognitive deficits
in patients with AD [28,35]. Here, we found that a 2-month
BCAA supplementation combined with HFD was sufficient
to increase soluble tau pSer202 (194%), pSer202/Thr205
(1271%), pThr231 (1680%), and pThr181 (193%)
compared with control mice, without changing the level of
total tau (Fig. 5A–D). Strikingly, phosphorylation of
detergent-insoluble tau at pSer202 was also increased in
the HFD-high group (1151%), whereas tau pSer396/404
and both total tau and total human tau were unchanged
(Fig. 5E–H). In contrast, reducing the BCAA resulted in a
tau phosphorylation status similar to mice fed the CD. How-
ever, we did not find any changes in protein levels of the
main kinases involved in tau phosphorylation
(Supplementary Table 5).
Accumulation of brain Ab peptides and extracellular pla-
ques are key markers of AD replicated in the 3xTg-AD
mouse [25,28]. However, we did not observe any effect of
BCAA consumption on Ab40 or Ab42 peptides in soluble
or detergent-insoluble fractions (Fig. 5I, J). Finally, we
found that the cytochrome oxidase protein, a marker of
cellular activity, was greatly increased in the cortex of
mice fed the HFD supplemented with BCAA (Fig. 5K).
No changes in drebrin (Fig. 5L) or other AD-relevant
markers were noted (Supplementary Table 5).4. Discussion
The consumption of high levels of BCAA is prevalent in
our contemporary society, but no study to our knowledge has
directly probed for the impact of high or low BCAA intake in


















































































































































































































Fig. 2. High or low BCAA dietary intake modifies plasmatic and cerebral amino acids levels in 18-month-old 3xTg-AD mice. BCAA (Val, Leu, Ile) and AAA
(Phe, Trp, Tyr, His) in intracardiac blood sampled just before perfusion, expressed as a ratio on total plasma amino acids (n5 4–6 per group) (A–C). BCAA and
AAA in TBS-soluble fraction of cortex homogenates, expressed as a ratio on total protein content (n 5 10–16 per group) (D–F). Data are presented as
mean 6 SEM. Two-way ANOVA, followed by Tukey’s HSD; effect of the diet: &P , .05, &&P , .01, &&&&P , .0001; effect of BCAA: ε different from
ctl, 1 different from high,  different from low. Abbreviations: CD, control diet; HFD, high-fat diet; ctl, normal levels of BCAA; high, BCAA-
supplemented diet by 50%; low, BCAA-reduced diet by 50%; AAA, aromatic amino acid; BCAA, branched-chain amino acid.
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Fig. 3. High or low BCAA supplies modify monoamines levels in 18-
month-old 3xTg-AD mice. Levels of dopamine and serotonin and their me-
tabolites measured in the prefrontal cortex (A–E) and hippocampus (F, G).
Data are presented as mean6 SEM. One-way ANOVA, Kruskal-Wallis fol-
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require controlled intervention difficult to achieve in a
clinical setting. In this study, 3xTg-AD mice were either
supplemented or restricted in BCAA over a CD or HFD
from 16 to 18 months of age. We found that BCAA
supplementation combined with a HFD resulted in a
significant mortality rate and strongly increased tau
neuropathology. In contrast, reducing BCAA in both the
CD and HFD did not result in any premature death,
improved cognitive performance, and led to increased
levels of threonine, tryptophan, 5-HT, 5-HIAA, and DOPAC
in the brain.
4.1. BCAA toxicity
A first striking consequence of BCAA supplementation
when combined with an HFD was a shortening of the life-
span of 3xTg-AD mice. Rises in plasmatic alanine amino-
transferase, aspartate aminotransferase, and creatine kinase
were observed in moribund animals and represent a possible
signature of hepatic and muscular toxicity, corroborating
previous studies reporting BCAA-induced liver injuries in
HFD-fed obese mice, inflammation and oxidative stress
[33,37]. Although the cause of death for all the animals
included in our study is not definitive, major brain
damages (atrophy, edema, etc.) were not observed,
suggesting that hepatic and muscular toxicity played a
more direct role in their premature death. Although little is
known about BCAA metabolism in the elderly, some
studies have revealed that the response to BCAA
supplementation is different in old age [38]. Thus, 18-
month-old 3xTg-AD mice could display a failure in catabo-
lizing BCAA, thus disturbing amino acids homeostasis in
the brain and peripheral tissues.
4.2. Modulation of amino acids by BCAA intake: Plasma
and brain levels
Our results further confirm that BCAA dietary supply
modulates plasma and brain amino acids and catechol-
amines. Perhaps surprisingly, BCAA supplementation was
not accompanied by a significant increase in plasmatic and
cortical concentrations in the 3xTg-AD mouse, but rather
by higher levels of asparagine in the plasma and lower
cortical threonine. It should be kept in mind that the present
measurement reflect an equilibrium reached following 2
months of altered BCAA intake, which is also affected by
other factors such as distribution of amino acids in tissue
where they integrate into proteins and elimination (meta-
bolism and renal clearance). Still, BCAA restriction loweredlowed by Dunn’s: *P, .05. Abbreviations: CD, control diet; HFD, high-fat
diet; BCAA, branched-chain amino acid; ctl, normal levels of BCAA; high,
BCAA-supplemented diet by 50%; low, BCAA-reduced diet by 50%; 5-HT,
serotonin; 5-HIAA, 5-hydroxyindoleacetic acid; DA, dopamine; DOPAC,
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Fig. 4. BCAA-reduced diet improves object recognitionmemory in 18-month-old 3xTg-ADmice. The novel object recognition test paradigm (A). Performance
at the novel object recognition task of 18-month-old 3xTg-AD mice determined with the recognition index (5 time exploring the novel object/total time
exploring both objects) (B) and the time spent exploring the old and the novel objects (C). Voluntary horizontal movement (D) measured during a 1-hour
open field test. Correlation between cortical threonine levels and recognition index of the mice (E). Dotted line represents a recognition index of 50%, meaning
the mouse does not discriminate between both objects. Almost all mice under the BCAA-supplemented HFD died before the test. Data are presented as
mean 6 SEM. One-sample t-test: *P , .05, **P , .01 versus random chance (recognition index of 50%). Wilcoxon signed-rank test (nonparametric paired
t-test): &P, .05. Pearson’s coefficient (r2) was determined using linear regression: ##P, .01. X: insufficient number of healthymice. Abbreviations: CD, control
diet; HFD, high-fat diet; ctl, normal levels of BCAA; high, BCAA-supplemented diet by 50%; low, BCAA-reduced diet by 50%; BCAA, branched-chain amino
acid.
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whereas in the cortex, levels of threonine and tryptophan
were upregulated, suggesting complex interactions in amino
acid homeostasis.
Previous studies have shown that BCAA administration
decreases cortical tyrosine and tryptophan in the hippocam-
pus of rats [39]. The likely mechanism is competition for
amino acid transporters at the blood-brain barrier [12].
However, despite obvious trends in the means, no signifi-
cant change in brain tyrosine content was detected here
due to interindividual variation. More clearly, increases
and decreases in BCAA intake induced a strong modula-
tion in cortical concentrations of threonine, possibly due
to the fact that brain uptake of threonine is highly sensitive
to competition from BCAA [40]. Finally, although we did
not observe a decrease in serotonin following BCAA sup-
plementation as previously reported [15,39], a 2-month
reduction in dietary BCAA combined to a HFD led to a
trend toward increased serotonin and dopamine levels.This tendency was supported by significant increases in se-
rotonin metabolite 5-HIAA and dopamine metabolite
DOPAC, changes typically interpreted as signs of increased
secretion and metabolism of these neurotransmitters [41].
Overall, our results confirm that BCAA dietary supply
modulates plasmatic and cerebral amino acids and neuro-
transmitters, thus providing a means by which they can
modify brain homeostasis and function.4.3. BCAA and memory
The observed failure of 18-month-old 3xTg-AD mice to
recognize the novel object is consistent with previous
work in the same model at similar ages [5,24,25]. As old
transgenic mice did not recognize the novel object, it was
predictable that further deterioration of memory could not
be detected at this age even after BCAA supplementation.
However, a 2-month reduction in BCAA intake improved





























































































































































































I J K L































































































































CP13 60 TauC 60 Tau13 60
CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD
CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD
CD
lowctl high lowctl high
HFD CD
lowctl high lowctl high
HFD CD















10 15 16 12 11 11
CD

































Fig. 5. BCAA-supplemented HFD worsens tau pathology but not amyloid pathology in 18-month-old 3xTg-AD mice. TBS-soluble tau phosphorylation at
pSer202, pSer202/Thr205, pThr231, and pThr181 (A–D), detergent-insoluble tau phosphorylation at pSer202 and pSer396/404 (E, F), detergent-insoluble total
tau and total human tau (G, H), TBS-soluble and detergent-insolubleAb42/Ab40 (I, J), detergent-soluble cytochrome oxidase 1 (K), and ratio of detergent-soluble
on TBS-soluble drebrin (L) measured byWestern blot in cortex homogenates. Data for tau phosphorylation were calculated as the ratio of the phosphoepitope to
total tau concentration. Data are presented as mean6 SEM. One-way ANOVA, Dunnett’s (vs CD) post hoc analysis: *P, .05, **P, .01. Representative bands
were selected from nonconsecutive samples run on the same gel. Abbreviations: BCAA, branched-chain amino acid; CD, control diet; HFD, high-fat diet; ctl,
normal levels of BCAA; high, BCAA-supplemented diet by 50%; low, BCAA-reduced diet by 50%; OD, optical density; Ab, amyloid b.
M. Tournissac et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 677-687 685These results were intriguing because HFD is known to
worsen cognitive defects in 3xTg-AD mice [24]. The
observed increase in cortical amino acids and monoamines
may underlie these memory improvements, as suggested
by the fact that the animals with the higher levels of brain
threonine performed better at the novel object recognition
task. In particular, threonine, tryptophan, and serotonin are
known to be involved in behavioral changes [15,42].4.4. BCAA and AD neuropathology
BCAA have been only recently implicated in AD. Plas-
matic valine has been linked to cognitive score and brain
atrophy in an AD cohort [20], while a recent Mendelian
randomization analysis indicates that genetic susceptibility
to high plasmatic isoleucine is associated with a higher risk
of developing the disease [22].APP/PS1mice, amousemodel
M. Tournissac et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 677-687686of amyloid pathology, spontaneously display increased plas-
matic BCAA, without obesity, suggesting that AD
pathology potentiates defects in BCAA metabolism, putting
patients with AD at a higher risk of BCAA-induced brain
damages [43,44]. Conversely, tau pathology is one of
the major neuropathological markers of AD, strongly
associated with antemortem cognitive deficits [35,45]. We
found that a 2-month BCAA supplementation combined
with a HFD strongly increased both soluble and detergent-
insoluble tau hyperphosphorylation in the cortex of old
3xTg-AD mice. These results suggest that the combination
of BCAA supplementation and HFD has synergistic delete-
rious effects on AD pathology and neuronal function. To
our knowledge, it is the first time that BCAAsupplementation
has been implicated in tau phosphorylation. Although synap-
tic and amyloid pathologies were unaffected by BCAAmod-
ulation, the rise in cytochrome oxidase 1 protein in cortex
homogenates of mice under BCAA-supplemented HFD
suggests an increase in mitochondrial oxidative activity in
those mice, possibly reflecting a state of neuronal oxidative
stress [46].
5. Conclusion
There is scientific evidence that dietary intervention
can reduce the risk of developing age-related cognitive
impairment or AD [3,47]. Thus, nutritional strategies
aimed at reducing AD pathology are of interest in the
field. This study provides controlled preclinical data
pinpointing the specific role of BCAA in an animal
model of AD. For the first time, our results identify the
potential risks of combining high BCAA consumption
with a HFD, not only regarding peripheral toxicity but
also with respect to the aggravation of AD-like tau neuro-
pathology. On a more positive note, our results suggest
that reducing the BCAA content in the diet supply, while
maintaining protein intake, could have a beneficial effect
on memory and could be considered in nutritional inter-
ventions aimed at improving cognitive performance
and/or reducing the incidence of AD. Thus, it would be
interesting to test whether protein supplementation with
low BCAA concentration could prevent mood and mem-
ory impairment. Another easier intervention for the
elderly would be to promote foods rich in protein but
low in BCAA [36].Acknowledgments
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1. Systematic review: We performed an extensive liter-
ature review using PubMed on branched-chain
amino acids (BCAA) and brain function. Although
BCAA are now increasingly studied in metabolic
disorders, very little is known on BCAA in the field
of Alzheimer’s disease (AD).
2. Interpretation: Our findings in a mouse model of AD
reveal that high and low BCAA consumption modu-
lates amino acid and monoamines levels in the brain
as well as AD neuropathology and memory-related
behavior.
3. Future directions: Intervention and observational
studies are needed to confirm whether high or low
BCAA consumption could increase or decrease,
respectively, the risk of developing dementia.References
[1] Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The
global prevalence of dementia: a systematic review and metaanalysis.
Alzheimers Dement 2013;9:63–75.e2.
[2] Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for
primary prevention of Alzheimer’s disease: an analysis of population-
based data. Lancet Neurol 2014;13:788–94.
[3] Ngandu T, Lehtisalo J, Solomon A, Lev€alahti E, Ahtiluoto S,
Antikainen R, et al. A 2 year multidomain intervention of diet, exer-
cise, cognitive training, and vascular risk monitoring versus control
to prevent cognitive decline in at-risk elderly people (FINGER): a
randomised controlled trial. Lancet 2015;385:2255–63.
[4] Kerdiles O, Laye S, Calon F. Omega-3 polyunsaturated fatty acids and
brain health: Preclinical evidence for the prevention of neurodegener-
ative diseases. Trends Food Sci Technol 2017;69:203–13.
[5] Dal-Pan A, Dudonne S, Bourassa P, Bourdoulous M, Tremblay C,
Desjardins Y, et al. Cognitive-Enhancing effects of a polyphenols-
rich extract from fruits without changes in neuropathology in an ani-
mal model of Alzheimer’s disease. J Alzheimers Dis 2017;55:115–35.
[6] Van de Rest O, Van der Zwaluw NL, de Groot LCPGM. Literature re-
view on the role of dietary protein and amino acids in cognitive func-
tioning and cognitive decline. Amino Acids 2013;45:1035–45.
[7] Ohtani M, Sugita M, Maruyama K. Amino acid mixture improves
training efficiency in athletes. J Nutr 2006;136:538S–43.
[8] Maughan RJ, Depiesse F, Geyer H, International Association of Ath-
letics Federations. The use of dietary supplements by athletes. J Sports
Sci 2007;25:S103–13.
[9] Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF,
et al. A Branched-Chain Amino Acid-Related Metabolic Signature
M. Tournissac et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 677-687 687that Differentiates Obese and Lean Humans and Contributes to Insulin
Resistance. Cell Metab 2009;9:311–26.
[10] Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al.
Metabolite profiles and the risk of developing diabetes. Nat Med 2011;
17:448–53.
[11] Newgard CB. Interplay between lipids and branched-chain amino acids
in development of insulin resistance. Cell Metab 2012;15:606–14.
[12] PardridgeWM.Kinetics of competitive inhibition of neutral amino acid
transport across the blood-brain barrier. J Neurochem 1977;28:103–8.
[13] Fernstrom JD. Large neutral amino acids: dietary effects on brain
neurochemistry and function. Amino Acids 2013;45:419–30.
[14] Gijsman HJ, Scarna A, Harmer CJ, McTavish SB, Odontiadis J,
Cowen PJ, et al. A dose-finding study on the effects of branch chain
amino acids on surrogate markers of brain dopamine function. Psycho-
pharmacology (Berl) 2002;160:192–7.
[15] Coppola A, Wenner BR, Ilkayeva O, Stevens RD, Maggioni M,
Slotkin TA, et al. Branched-chain amino acids alter neurobehavioral
function in rats. Am J Physiol Endocrinol Metab 2013;304:E405–13.
[16] Scaini G, Jeremias GC, Furlanetto CB, Dominguini D, Comim CM,
Quevedo J, et al. Behavioral responses in rats submitted to chronic
administration of branched-chain amino acids. JIMD Rep 2014;
13:159–67.
[17] Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, et al. Neurotransmitter recep-
tors and cognitive dysfunction in Alzheime’s disease and Parkinson’
disease. Prog Neurobiol 2012;97:1–13.
[18] Zinnanti WJ, Lazovic J. Interrupting the mechanisms of brain injury in
a model of maple syrup urine disease encephalopathy. J Inherit Metab
Dis 2012;35:71–9.
[19] Sitta A, Ribas GS, Mescka CP, Barschak AG, Wajner M, Vargas CR.
Neurological damage in MSUD: the role of oxidative stress. Cell
Mol Neurobiol 2014;34:157–65.
[20] Toledo JB, Arnold M, Kastenm€uller G, Chang R, Baillie RA, Han X,
et al. Metabolic network failures in Alzheimer’s disease: A biochem-
ical road map. Alzheimers Dement 2017;13:965–84.
[21] Tynkkynen J, Chouraki V, van der Lee SJ, Hernesniemi J, Yang Q,
Li S, et al. Association of branched-chain amino acids and other circu-
lating metabolites with risk of incident dementia and Alzheimer’s dis-
ease: A prospective study in eight cohorts. Alzheimers Dement 2018;
14:723–33.
[22] Larsson SC, Markus HS. Branched-chain amino acids and Alz-
heimer’s disease: a Mendelian randomization analysis. Nat Publishing
Group 2017;7:13604.
[23] Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P,
et al. High-fat diet aggravates amyloid-beta and tau pathologies in
the 3xTg-AD mouse model. Neurobiol Aging 2010;31:1516–31.
[24] Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V,
et al. Insulin reverses the high-fat diet-induced increase in brain ab and
improves memory in an animal model of Alzheimer disease. Diabetes
2014;63:4291–301.
[25] St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg
protects the 3xTg-AD mouse model of Alzheimer’s disease from
memory deficit and Ab pathology. J Neuroinflammation 2014;11:54.
[26] Robbins RJ, Leonczak J, Johnson JC, Li J, Kwik-Uribe C, Prior RL,
et al. Method performance and multi-laboratory assessment of a
normal phase high pressure liquid chromatography-fluorescence
detection method for the quantitation of flavanols and procyanidins
in cocoa and chocolate containing samples. J Chromatogr A 2009;
1216:4831–40.
[27] Crumeyrolle-Arias M, Jaglin M, Bruneau A, Vancassel S, Cardona A,
Dauge V, et al. Absence of the gut microbiota enhances anxiety-like
behavior and neuroendocrine response to acute stress in rats. Psycho-
neuroendocrinology 2014;42:207–17.
[28] Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010;
362:329–44.[29] Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA,
Hall KS, et al. Trends in the incidence and prevalence of Alzheimer’s
disease, dementia, and cognitive impairment in the United States.
Alzheimers Dement 2011;7:80–93.
[30] Wang DD, Leung CW, Li Y, Ding EL, Chiuve SE, Hu FB, et al. Trends
in dietary quality among adults in the United States, 1999 through
2010. JAMA Intern Med 2014;174:1587–95.
[31] Reitz C, Tang M-X, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A
summary risk score for the prediction of Alzheimer disease in elderly
persons. Arch Neurol 2010;67:835–41.
[32] Theriault P, ElAli A, Rivest S. High fat diet exacerbates Alzheimer’s
disease-related pathology in APPswe/PS1 mice. Oncotarget 2016;5.
[33] Zhang F, Zhao S, Yan W, Xia Y, Chen X, Wang W, et al. Branched
Chain Amino Acids Cause Liver Injury in Obese/Diabetic Mice by
Promoting Adipocyte Lipolysis and Inhibiting Hepatic Autophagy.
EBioMedicine 2016;13:157–67.
[34] Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, et al.
Lower serum creatinine is a new risk factor of type 2 diabetes: the Kan-
sai healthcare study. Diabetes Care 2009;32:424–6.
[35] Tremblay C, Francois A, Delay C, Freland L, Vandal M, Bennett, et al.
Association of neuropathological markers in the parietal cortex with
antemortem cognitive function in persons with mild cognitive impair-
ment andAlzheimerDisease. J Neuropathol ExpNeurol 2017;76:70–88.
[36] Rajendram R, Preedy VR, Patel VB. Branched Chain Amino Acids in
Clinical Nutrition. New-York, NY: Humana Press; 2015.
[37] Zhenyukh O, Civantos E, Ruiz-Ortega M, Sanchez MS, Vazquez C,
Peiro C, et al. High concentration of branched-chain amino acids pro-
motes oxidative stress, inflammation and migration of human periph-
eral blood mononuclear cells via mTORC1 activation. Free Radic Biol
Med 2017;104:165–77.
[38] Tatpati LL, Irving BA, Tom A, Bigelow ML, Klaus K, Short KR, et al.
The effect of branched chain amino acids on skeletal muscle mito-
chondrial function in young and elderly adults. J Clin Endocrinol
Metab 2010;95:894–902.
[39] Choi S, Disilvio B, Fernstrom MH, Fernstrom JD. Oral branched-
chain amino acid supplements that reduce brain s during exercise in
rats also lower brain catecholamines. Amino Acids 2013;45:1133–42.
[40] Tovar A, Tews JK, Torres N, Harper AE. Some characteristics of thre-
onine transport across the blood-brain barrier of the rat. J Neurochem
1988;51:1285–93.
[41] Burchinsky SG, Kuznetsova SM. Brain monoamine oxidase and
aging: a review. Arch Gerontol Geriatr 1992;14:1–15.
[42] Markus CR. Dietary amino acids and brain serotonin function; impli-
cations for stress-related affective changes. Neuromolecular Med
2008;10:247–58.
[43] Ruiz HH, Chi T, Shin AC, Lindtner C, Hsieh W, Ehrlich M, et al.
Increased susceptibility to metabolic dysregulation in a mouse model
of Alzheimer’s disease is associated with impaired hypothalamic insu-
lin signaling and elevated BCAA levels. Alzheimers Dement 2016;
12:851–61.
[44] Gonzalez-Domınguez R, Garcıa-Barrera T, Vitorica J, Gomez-
Ariza JL. Metabolomic investigation of systemic manifestations asso-
ciated with Alzheimer’s disease in the APP/PS1 transgenic mouse
model. Mol Biosyst 2015;11:2429–40.
[45] Tremblay C, Pilote M, Phivilay A, Emond V, Bennett CF. Biochemical
characterization of Abeta and tau pathologies in mild cognitive impair-
ment and Alzheimer’s disease. J Alzheimers Dis 2007;12:377–90.
[46] Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, et al. Mito-
chondrial abnormalities and oxidative imbalance in Alzheimer dis-
ease. J Alzheimers Dis 2006;9:147–53.
[47] Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS,
Blackwell A, et al. Beneficial effects of docosahexaenoic acid on
cognition in age-related cognitive decline. Alzheimers Dement
2010;6:456–64.
